Chardan initiated coverage of Reviva Pharmaceuticals (RVPH) with a Buy rating and $2 price target The firm cites the potential of the company’s lead asset brilaroxazine as a next-generation antipsychotic product for the Buy rating. Reviva’s brilaroxazine is a “real product” that could get approval in schizophrenia and find a niche in a large but highly genericized market, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva Pharmaceuticals Amends Bylaws to Ease Quorum
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Reviva Pharmaceuticals Announces Public Offering to Raise Funds
- Why Is Reviva Pharmaceuticals Stock (RVPH) Down 40% Today?
- Reviva Pharmaceuticals price target lowered to $2 from $3 at D. Boral Capital